U.S. markets closed

Bristol-Myers Squibb Company (BMY)

NYSE - NYSE Delayed Price. Currency in USD
72.45-0.54 (-0.74%)
At close: 04:00PM EST
72.75 +0.30 (+0.41%)
After hours: 07:45PM EST

Bristol-Myers Squibb Company

430 East 29th Street
14th Floor
New York, NY 10016
United States
212 546 4000

IndustryDrug Manufacturers—General
Full Time Employees32,200

Key Executives

NameTitlePayExercisedYear Born
Dr. Giovanni Caforio M.D.Chairman & CEO5.82MN/A1965
Mr. David V. ElkinsExec. VP & CFO3.18M1.3M1968
Ms. Sandra Leung Esq.Exec. VP & Gen. Counsel2.73MN/A1961
Dr. Christopher S. BoernerExec. VP & Chief Commercialization Officer2.61MN/A1971
Mr. Rupert Vessey BCH, BM, DPHIL, M.A.Exec. VP and Pres of Research & Early Devel.3.21M1.45M1965
Mr. Greg MeyersExec. VP and Chief Digital & Technology OfficerN/AN/A1973
Mr. Timothy PowerVP & Head of Investor RelationsN/AN/AN/A
Ms. Cari GallmanSr. VP & Chief Compliance and Ethics OfficerN/AN/AN/A
Ms. Ann M. Powell JudgeExec. VP & Chief HR OfficerN/AN/A1966
Mr. Jitendra TyagiHead of US Drug Makers - IndiaN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Corporate Governance

Bristol-Myers Squibb Company’s ISS Governance QualityScore as of January 28, 2023 is 2. The pillar scores are Audit: 8; Board: 5; Shareholder Rights: 3; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.